Nanobac Pharmaceuticals stock analysis
Nanobac Pharmaceuticals (NNBP) Stock Price & Analysis
NNBP Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- $250
- Enterprise Value
- N/A
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- $5.37M
- Price to Earnings (P/E)
- 0.0
- Beta
- 21.53
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
NNBP FAQ
What is Nanobac Pharmaceuticals’s market cap?
When is Nanobac Pharmaceuticals’s upcoming earnings report date?
Is Nanobac Pharmaceuticals overvalued?
Does Nanobac Pharmaceuticals pay dividends?
What is Nanobac Pharmaceuticals’s EPS estimate?
How many shares outstanding does Nanobac Pharmaceuticals have?
Which hedge fund is a major shareholder of Nanobac Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Nanobac Pharmaceuticals
Nanobac Pharmaceuticals, Incorporated is dedicated to advancing human health through the creation and refinement of products and services designed for the identification and management of calcifying nanoparticles (CNPs). The company's offerings include the production and sale of in vitro diagnostic (IVD) kits, which encompass assays, antibodies, and reagents specifically developed for detecting CNPs. Notably, their diagnostic assays include NANO-CAPTURE and NANO-SERO. Furthermore, Nanobac engages in research and clinical studies focused on various urological diseases—such as chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases—as well as cardiovascular ailments. Established in 1994 and headquartered in Tampa, Florida, the company operated as HealthCentrics Inc. until its name change to Nanobac Pharmaceuticals, Incorporated in December 2002.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Stanton
- Employees
- 1
- Website
- www.nanobac.com
- Address
- 3000 Bayport Drive, Tampa, FL, 33607, US

